Prot #PAC203: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib

Project: Research project

Project Details

StatusActive
Effective start/end date10/25/17 → 10/25/23

Funding

  • PSI Pharma Support America Inc. (Prot #PAC203)
  • CTI BioPharma Corp. (Prot #PAC203)